John M. Lachin
#92,320
Most Influential Person Now
Researcher
John M. Lachin's AcademicInfluence.com Rankings
John M. Lachinengineering Degrees
Engineering
#2220
World Rank
#3094
Historical Rank
Electrical Engineering
#370
World Rank
#416
Historical Rank
John M. Lachincomputer-science Degrees
Computer Science
#3160
World Rank
#3311
Historical Rank
Algorithms
#80
World Rank
#80
Historical Rank
Computational Linguistics
#120
World Rank
#123
Historical Rank
Machine Learning
#308
World Rank
#312
Historical Rank
Download Badge
Engineering Computer Science
John M. Lachin's Degrees
- PhD Computer Science University of California, Berkeley
- Masters Electrical Engineering Stanford University
Similar Degrees You Can Earn
Why Is John M. Lachin Influential?
(Suggest an Edit or Addition)John M. Lachin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long‐Term Complications in Insulin‐Dependent Diabetes Mellitus (1993) (19715)
- Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. (2002) (17532)
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. (2015) (4686)
- Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. (2005) (4036)
- Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. (2006) (2910)
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. (2016) (2348)
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. (2015) (1907)
- Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. (2000) (1434)
- Introduction to sample size determination and power analysis for clinical trials. (1981) (954)
- Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. (2009) (878)
- Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. (2003) (832)
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial (2016) (822)
- Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. (2002) (816)
- Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. (2003) (631)
- Statistical considerations in the intent-to-treat principle. (2000) (605)
- Achieving weight and activity goals among diabetes prevention program lifestyle participants. (2004) (517)
- Rosiglitazone-Associated Fractures in Type 2 Diabetes (2008) (509)
- Differences in A1C by Race and Ethnicity Among Patients With Impaired Glucose Tolerance in the Diabetes Prevention Program (2007) (497)
- How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (2017) (492)
- Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. (2011) (465)
- C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. (2004) (462)
- Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited (2008) (460)
- A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. (1992) (455)
- Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Contro (1999) (441)
- Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety. (1981) (419)
- Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up (2016) (395)
- Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. (2015) (362)
- Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. (1986) (358)
- Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. (2003) (351)
- Biostatistical Methods: The Assessment of Relative Risks (2000) (345)
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. (2015) (332)
- Effect of Prior Intensive Insulin Treatment During the Diabetes Control and Complications Trial (DCCT) on Peripheral Neuropathy in Type 1 Diabetes During the Epidemiology of Diabetes Interventions and Complications (EDIC) Study (2010) (330)
- Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. (2008) (327)
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease (2018) (318)
- Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. (2011) (311)
- Implications of the United kingdom prospective diabetes study. (2003) (300)
- Two-Sample Asymptotically Distribution-Free Tests for Incomplete Multivariate Observations (1984) (294)
- Effects of Prior Intensive Insulin Therapy on Cardiac Autonomic Nervous System Function in Type 1 Diabetes Mellitus: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) (2009) (273)
- Properties of the urn randomization in clinical trials. (1988) (266)
- Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study (2010) (263)
- Randomization in clinical trials: conclusions and recommendations. (1988) (262)
- The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study (2006) (258)
- A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. (2002) (249)
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions (2013) (247)
- Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 Diabetes (2008) (245)
- Fall in C-Peptide During First 2 Years From Diagnosis (2012) (243)
- Properties of permuted-block randomization in clinical trials. (1988) (239)
- Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients With Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC (2014) (231)
- The natural history of cholelithiasis: the National Cooperative Gallstone Study. (1984) (221)
- Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®) (2015) (215)
- Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) (2013) (212)
- The role of measurement reliability in clinical trials (2004) (210)
- Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT (2011) (202)
- Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial (2018) (201)
- Evaluating the Role of Epigenetic Histone Modifications in the Metabolic Memory of Type 1 Diabetes (2014) (196)
- Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. (2016) (195)
- Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) (2014) (190)
- Randomization in Clinical Trials: Theory and Practice (2002) (188)
- Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes (2006) (187)
- A review of methods for futility stopping based on conditional power (2005) (183)
- Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (2013) (182)
- Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial (2014) (178)
- Natural history and course of acquired lactic acidosis in adults (1994) (177)
- Relationship of Glycated Albumin to Blood Glucose and HbA1c Values and to Retinopathy, Nephropathy, and Cardiovascular Outcomes in the DCCT/EDIC Study (2013) (176)
- Statistical properties of randomization in clinical trials. (1988) (176)
- Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort (2016) (173)
- Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. (2010) (172)
- Fallacies of last observation carried forward analyses (2016) (166)
- Progression of Carotid Artery Intima-Media Thickness During 12 Years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study (2011) (157)
- Worst-rank score analysis with informatively missing observations in clinical trials. (1999) (156)
- The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results (2009) (154)
- Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data (1988) (149)
- Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. (2009) (144)
- Properties of simple randomization in clinical trials. (1988) (142)
- Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population (2016) (134)
- Erratum: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: Report of an ADA workshop, 21-22 October 2001 (Diabetes (2004) 53 (250-264)) (2004) (134)
- Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. (1992) (134)
- Risk Factors for Cardiovascular Disease in Type 1 Diabetes (2016) (130)
- Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial (2017) (129)
- DCCT and EDIC Studies in Type 1 Diabetes: Lessons for Diabetic Neuropathy Regarding Metabolic Memory and Natural History (2010) (125)
- Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. (2014) (120)
- Failure to Preserve β-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes (2010) (119)
- Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. (2008) (115)
- Skin Advanced Glycation End Products Glucosepane and Methylglyoxal Hydroimidazolone Are Independently Associated With Long-term Microvascular Complication Progression of Type 1 Diabetes (2014) (112)
- A Genome-Wide Association Study Identifies a Novel Major Locus for Glycemic Control in Type 1 Diabetes, as Measured by Both A1C and Glucose (2009) (112)
- The use of response-adaptive designs in clinical trials. (1993) (111)
- Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk (2017) (107)
- Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study (2017) (104)
- Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. (1992) (104)
- Multiple Superoxide Dismutase 1/Splicing Factor Serine Alanine 15 Variants Are Associated With the Development and Progression of Diabetic Nephropathy (2008) (103)
- Pretreatment biliary lipid composition in white patients with radiolucent gallstones in the National Cooperative Gallstone Study. (1982) (102)
- National Cooperative Gallstone Study: the effect of chenodeoxycholic acid on lipoproteins and apolipoproteins. (1982) (99)
- The Effect of Intensive Diabetes Treatment on Resting Heart Rate in Type 1 Diabetes (2007) (99)
- Type 1 Diabetes TrialNet–An International Collaborative Clinical Trials Network (2008) (98)
- Parametric survival models for interval-censored data with time-dependent covariates. (2006) (95)
- Effect of rituximab on human in vivo antibody immune responses. (2011) (94)
- Levels of Oxidized LDL and Advanced Glycation End Products–Modified LDL in Circulating Immune Complexes Are Strongly Associated With Increased Levels of Carotid Intima-Media Thickness and Its Progression in Type 1 Diabetes (2011) (93)
- Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program (2007) (87)
- Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study (2019) (87)
- Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. (2016) (84)
- Myocardial Structure, Function, and Scar in Patients With Type 1 Diabetes Mellitus (2011) (83)
- Validity and Reproducibility of Measurement of Islet Autoreactivity by T-Cell Assays in Subjects With Early Type 1 Diabetes (2009) (82)
- Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. (2011) (81)
- Frequency of Evidence‐Based Screening for Retinopathy in Type 1 Diabetes (2017) (81)
- Intensive diabetes therapy and ocular surgery in type 1 diabetes. (2015) (77)
- Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. (2016) (73)
- Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study (2020) (73)
- The Hemoglobin Glycation Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control and Complications Trial (2007) (71)
- Renal outcomes in patients with type 1 diabetes and macroalbuminuria. (2014) (70)
- A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe (2006) (69)
- Sample size determinants for r X c comparative trials. (1977) (68)
- Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. (2011) (67)
- Implementation of group sequential logrank tests in a maximum duration trial. (1990) (67)
- Increased T Cell Proliferative Responses to Islet Antigens Identify Clinical Responders to Anti-CD20 Monoclonal Antibody (Rituximab) Therapy in Type 1 Diabetes (2011) (65)
- Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. (2010) (63)
- Randomization in Clinical Trials: Rosenberger/Randomization in Clinical Trials (2016) (62)
- Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial (2017) (62)
- Failure to Preserve beta-cell function with Mycophenolate Mofetil and Daclizumab Combined Therapy in patients with new onset Type 1 Diabetes Running title: MMF and DZB in New Onset T1D (2010) (61)
- Hypertension, Insulin, and Proinsulin in Participants With Impaired Glucose Tolerance (2002) (58)
- Depression as a symptom of alcoholism: search for a phenomenon. (1968) (58)
- Circulating vitamin D metabolites and kidney disease in type 1 diabetes. (2012) (57)
- The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study (2017) (57)
- Power and sample size evaluation for the McNemar test with application to matched case-control studies. (1992) (56)
- Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype (2018) (55)
- The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. (2013) (52)
- Interim analyses with repeated measurements in a sequential clinical trial (1990) (50)
- Low-dose chenodiol to prevent gallstone recurrence after dissolution therapy. (1984) (49)
- Risk Factors for Kidney Disease in Type 1 Diabetes (2019) (49)
- A Prospective Morphologic Evaluation of Hepatic Toxicity of Chenodeoxycholic Acid in Patients with Cholelithiasis: The National Cooperative Gallstone Study (2007) (48)
- Pancreatic Safety of Sitagliptin in the TECOS Study (2016) (47)
- Sample size evaluation for a multiply matched case–control study using the score test from a conditional logistic (discrete Cox PH) regression model (2008) (46)
- LINK-BASED MODELS FOR SURVIVAL DATA WITH INTERVAL AND CONTINUOUS TIME CENSORING (1997) (46)
- Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes (2015) (44)
- Design and methodological considerations in the National Cooperative Gallstone Study: a multicenter clinical trial. (1981) (44)
- Determining stability of stored samples retrospectively: the validation of glycated albumin. (2011) (43)
- Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. (2011) (43)
- Coprogression of Cardiovascular Risk Factors in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study (2016) (43)
- Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study (2020) (43)
- Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial (2013) (42)
- Factors Affecting the Decline in Incidence of Diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS) (2014) (42)
- Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain (2009) (42)
- Diabetes Prevention Program (DPP) (2020) (41)
- Group sequential distribution-free methods for the analysis of multivariate observations. (1992) (39)
- Haptoglobin Genotype and the Rate of Renal Function Decline in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (2013) (39)
- Association of Cardiovascular Risk Factors and Myocardial Fibrosis With Early Cardiac Dysfunction in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (2016) (38)
- The Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes: The DCCT/EDIC Trials. (2019) (37)
- High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. (2012) (37)
- The Randomized Clinical Trial and Therapeutic Decisions. (1983) (37)
- Ultrastructural Evidence of Intrahepatic Cholestasis Before and After Chenodeoxycholic Acid Therapy in Patients with Cholelithiasis: The National Cooperative Gallstone Study (2007) (36)
- Effects of Prior Intensive Versus Conventional Therapy and History of Glycemia on Cardiac Function in Type 1 Diabetes in the DCCT/EDIC (2013) (36)
- Gaps in the glycation gap hypothesis. (2011) (36)
- Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study (2014) (36)
- Distribution-free Confidence Intervals for Pr(X1 < X2) (1987) (35)
- Circulating Vitamin D Metabolites and Subclinical Atherosclerosis in Type 1 Diabetes (2013) (35)
- Sulfation of lithocholate as a possible modifier of chenodeoxycholic acid-induced elevations of serum transaminase in patients with gallstones. (1981) (35)
- Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study (2019) (34)
- Longitudinal changes in estimated and measured GFR in type 1 diabetes. (2014) (34)
- Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Type 1 Diabetes (2011) (33)
- Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. (2018) (33)
- Genetic Modulation of Lipid Profiles following Lifestyle Modification or Metformin Treatment: The Diabetes Prevention Program (2012) (33)
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. (2016) (31)
- Assessment of stratum-covariate interactions in Cox's proportional hazards regression model. (1986) (31)
- Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study (2019) (30)
- On stepwise discriminant analyses applied to physiologic data. (1974) (29)
- Use of spending functions for occasional or continuous monitoring of data in clinical trials. (1993) (28)
- Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial (2017) (28)
- The Efficacy of Tolrestat in the Treatment of Diabetic Peripheral Neuropathy: A meta-analysis of individual patient data (1996) (28)
- Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. (2021) (27)
- Newborn offspring of a schizophrenic parent: cardiac reactivity to auditory stimuli. (1975) (26)
- Aortic Distensibility in Type 1 Diabetes (2013) (26)
- Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience. (2019) (25)
- Applications of the Wei-Lachin Multivariate One-Sided Test for Multiple Outcomes on Possibly Different Scales (2014) (25)
- Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. (2021) (25)
- What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes? (2018) (25)
- Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit (2009) (25)
- DNA methylation age calculators reveal association with diabetic neuropathy in type 1 diabetes (2020) (24)
- DNA methylation mediates development of HbA1c-associated complications in type 1 diabetes (2020) (24)
- Heart rate and blood pressure in black newborns and in white newborns. (1976) (24)
- Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. (2018) (23)
- The effects of chenodiol on biliary lipids and their association with gallstone dissolution in the National Cooperative Gallstone Study (NCGS). (1984) (23)
- Estimators and tests in the analysis of multiple nonindependent 2 x 2 tables with partially missing observations. (1988) (23)
- Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort (2018) (22)
- The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. (2015) (22)
- Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes (2016) (21)
- Mass spectrometry identification of biliary bile acids in bile from patients with gallstones before and during treatment with chenodeoxycholic acid. An ancillary study of the National Cooperative Gallstone Study. (1985) (21)
- Point: Intensive Glycemic Control and Mortality in ACCORD—A Chance Finding? (2010) (21)
- Analysis of Count Data (2008) (20)
- Termination of a clinical trial with no treatment group difference: the Lupus Nephritis Collaborative Study. (1992) (20)
- Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study (2017) (20)
- Treatment protocols of the lupus nephritis collaborative study of plasmapheresis in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. (1990) (20)
- Application of the Wei–Lachin multivariate one-directional test to multiple event-time outcomes (2015) (20)
- Power and sample size evaluation for the Cochran–Mantel–Haenszel mean score (Wilcoxon rank sum) test and the Cochran–Armitage test for trend (2011) (20)
- Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes: response to McCarter et al. (2005) (19)
- Angiotensin converting enzyme inhibition in diabetic nephropathy (1994) (19)
- Significance of Epicardial and Intrathoracic Adipose Tissue Volume among Type 1 Diabetes Patients in the DCCT/EDIC: A Pilot Study (2016) (18)
- Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC) (2021) (18)
- Sequential clinical trials for normal variates using interval composite hypotheses. (1981) (17)
- Application of robust estimating equations to the analysis of quantitative longitudinal data (2001) (17)
- Pilot genome-wide association search identifies potential loci for risk of erectile dysfunction in type 1 diabetes using the DCCT/EDIC study cohort. (2012) (17)
- Haptoglobin 2-2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). (2016) (17)
- Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial) (2009) (17)
- Heart Rate Levels of Black and White Newborns (1974) (16)
- Progression of Electrocardiographic Abnormalities in Type 1 Diabetes During 16 Years of Follow‐up: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study (2016) (16)
- Over‐ruling a group sequential boundary—a stopping rule versus a guideline (2003) (16)
- Nonparametric Statistical Analysis. (2020) (16)
- Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough? (2019) (15)
- Sequential monitoring of survival data with the Wilcoxon statistic. (1995) (14)
- A comparison of the baseline metabolic profiles between Diabetes Prevention Trial‐Type 1 and TrialNet Natural History Study participants (2011) (14)
- Central laboratory quality control in the National Cooperative Gallstone Study. (1983) (13)
- Operating characteristics of sample size re‐estimation with futility stopping based on conditional power (2006) (13)
- The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes (2021) (13)
- Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (2017) (12)
- DNA methylation mediates HbA1c-associated complications development in Type 1 diabetes (2020) (12)
- Distribution-Free Marginal Analysis of Repeated Measures (1996) (12)
- A Controlled Clinical Trial of Angiotensin-Converting Enzyme Inhibition in Type I Diabetic Nephropathy: Study Design and Patient Characteristics (1992) (12)
- Diabetes Care Editors’ Expert Forum 2018: Managing Big Data for Diabetes Research and Care (2019) (12)
- Newborn Heart Rate and Blood Pressure: Relation to Race and to Socioeconomic Class (1976) (12)
- On a stepwise procedure for two population Bayes decision rules using discrete variables. (1973) (11)
- Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata (2013) (11)
- Group sequential monitoring of distribution-free analyses of repeated measures. (1997) (11)
- Immune Complexes and the Risk of CVD in Type 1 Diabetes (2019) (11)
- Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes (2021) (11)
- An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study (2020) (11)
- Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. (2022) (10)
- The Effect of Excess Weight Gain with Intensive Diabetes Treatment on Cardiovascular Disease Risk Factors and Atherosclerosis in Type 1 Diabetes: Results from the Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) Study (2012) (10)
- Validity of self-report in type 1 diabetic subjects for laser treatment of retinopathy. (2013) (10)
- Mediation of the association of smoking and microvascular complications by glycemic control in type 1 diabetes (2019) (10)
- Validation of a computer-assisted method for estimating the number and volume of gallstones visualized by cholecystography. (1981) (10)
- Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. (2022) (9)
- Stratified-adjusted versus unstratified assessment of sample size and power for analyses of proportions. (1995) (9)
- Power of the Mantel–Haenszel and other tests for discrete or grouped time‐to‐event data under a chained binomial model (2013) (9)
- Abstract 14811: Association of Cardiovascular Risk Factors and Myocardial Fibrosis with Early Cardiac Dysfunction in Type 1 Diabetes Mellitus: The Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and Complications (EDIC) Study (2014) (9)
- The Randomized clinical trial and therapeutic decisions (1984) (8)
- Maximum information designs (2005) (8)
- Optimal screening schedules for disease progression with application to diabetic retinopathy. (2018) (8)
- The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC). (2018) (8)
- Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC (2022) (8)
- Relation between carotid intima-media thickness and left ventricular mass in type 1 diabetes mellitus (from the Epidemiology of Diabetes Interventions and Complications [EDIC] Study). (2012) (8)
- Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients (2021) (8)
- Association of Baseline Characteristics With Insulin Sensitivity and β-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort (2020) (8)
- Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study. (2022) (7)
- Biomarkers of tubulointerstitial damage and function in type 1 diabetes (2017) (7)
- External monitoring of a data coordinating center: experience of the National Cooperative Gallstone Study. (1987) (7)
- Effect of GLP‐1 and GIP on C‐peptide secretion after glucagon or mixed meal tests: Significance in assessing B‐cell function in diabetes (2017) (7)
- Rosiglitazone Associated Fractures in Type 2 Diabetes: An Analysis From ADOPT (2008) (7)
- Conflicts of interest in data monitoring of industry versus publicly financed clinical trials (2004) (7)
- Response‐Adaptive Randomization (2005) (7)
- Severe hypoglycaemia in Diabetes Control and Complications Trial (1994) (7)
- Biliary bile acid composition and cholesterol saturation (1983) (6)
- Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care 2017;40:777–783 (2017) (6)
- Design of the Empagliflozin Cardiovascular (CV) Outcome Event Trial in Type 2 Diabetes (T2D) (2013) (6)
- Properties of randomization in clinical trials: Foreword (1988) (6)
- Sample Size, Power, and Efficiency (2008) (6)
- Randomization and the Clinical Trial (2005) (6)
- A flexible stochastic curtailing procedure for the log-rank test. (2000) (6)
- Moderation of the Effect of Glycemia on the Risk of Cardiovascular Disease in Type 1 Diabetes: the DCCT/EDIC Study. (2020) (5)
- Measuring adjustment in patients disabled with alcoholism. (1969) (5)
- The Society for Clinical Trials supports United States legislation mandating trials registration (2004) (5)
- Sample Size Determination (2005) (5)
- Frequency of Evidence-Based Screening for Diabetic Retinopathy. (2017) (5)
- The National Cooperative Gallstone Study viewed by its investigators. (1983) (5)
- The Effect of Interventions to Prevent Type 2 Diabetes on the Development of Diabetic Retinopathy: The DPP/DPPOS Experience (2022) (5)
- RISK FACTORS FOR HEARING IMPAIRMENT IN TYPE 1 DIABETES. (2019) (4)
- Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study. (2022) (4)
- Intensive Diabetes Therapy Reduces Ocular Surgeries in Patients with Type 1 Diabetes: twenty-eight year followup of the Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC) (2013) (4)
- Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study. (2022) (4)
- Corrections for Bias in Maximum Likelihood Parameter Estimates Due to Nuisance Parameters (2003) (4)
- Properties of composite time to first event versus joint marginal analyses of multiple outcomes (2018) (4)
- Refractive Error and Retinopathy Outcomes in Type 1 Diabetes: the DCCT/EDIC Study. (2020) (4)
- Phasic Heart Rate Responses: Different Patterns in Black and in White Newborns (1975) (4)
- Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 2020;69:291–299 (2020) (4)
- Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study (2021) (4)
- The National Cooperative Gallstone Study and current management of cholesterol cholelithiasis—Two views (1983) (4)
- The Levels of Oxidized LDL and AGE-LDL in Circulating Immune Complexes are strongly associated with increased levels of Carotid Intima-Media Thickness and its progression in Type 1 Diabetes Short title : Modified LDL in LDL-IC predict increased carotid IMT (2010) (4)
- Association of glycemia with insulin sensitivity and β-cell function in adults with early type 2 diabetes on metformin alone. (2021) (4)
- Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study (2018) (4)
- Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study (2018) (4)
- Shape of the OGTT glucose response curve: relationship with β-cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin (2021) (4)
- Perceptions of the coordinating center: foreword. (1980) (3)
- Major issues in the organization and implementation of the National Cooperative Gallstone Study (NCGS). (1984) (3)
- Effects of dose relative to body weight in the National Cooperative Gallstone Study: a fixed-dose trial. (1983) (3)
- Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. (2022) (3)
- Feasibility of low-dose and intermittent chenodeoxycholic acid therapy of gallstones (1977) (3)
- Measurement of electroencephalic evoked response: comparison of univariate and multivariate. (1976) (3)
- Issues in the Design of Clinical Trials (2005) (3)
- Biochemical Markers of Bone Turnover in Older Adults with Type 1 Diabetes. (2022) (3)
- The 2018 World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) score and diabetes risk in the Diabetes Prevention Program Outcomes Study (DPPOS) (2022) (3)
- Prevalence of microalbuminuria in recently diagnosed Type 2 diabetes mellitus and its relationship to non-traditional risk factors: observations from the ADOPT study (2003) (3)
- Abstracts of the 49th Annual Meeting of the EASD (2013) (2)
- THE NATIONAL COOPERATIVE GALLSTONE STUDY (2008) (2)
- Physical Function in Middle-aged and Older Adults With Type 1 Diabetes: Long-term Follow-up of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. (2022) (2)
- Logistic Regression Models (2011) (2)
- Erratum to: Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes (2015) (2)
- Response to Comment on: Lachin et al. (2007) The Hemoglobin Glycation Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control and Complications Trial: Diabetes 56:1913–1921, 2007 (2008) (2)
- Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. Diabetes Care 2017;40:655–662 (2018) (2)
- Martingales without tears (1995) (2)
- Closed testing using surrogate hypotheses with restricted alternatives (2019) (2)
- 703 GENOME WIDE ASSOCIATION STUDY IDENTIFIES NOVEL GENES FOR ERECTILE DYSFUNCTION RISK USING THE EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (EDIC) DATABASE (2010) (2)
- Group sequential large sample T2‐like χ2 tests for multivariate observations (2003) (2)
- A tribute to Samuel W. Greenhouse (2003) (2)
- Remembrances of Max Halperin. (1990) (2)
- Baseline characteristics of participants enrolled in the empagliflozin cardiovascular outcome trial (EMPA-REG OUTCOME™) in patients with type 2 diabetes (2014) (2)
- Probabilistic measures of cost‐effectiveness (2016) (2)
- Models to Assess the Association of a Semi-Quantitative Exposure With Outcomes. (2020) (2)
- DNA methylation age calculators reveal association with diabetic neuropathy in type 1 diabetes (2020) (2)
- 79 Link-based models for survival data with random interval and continuous time censoring (1997) (2)
- Worst-Rank Score Methods-A Nonparametric Approach to Informatively Missing Data. (2020) (2)
- Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies (2021) (2)
- The Effect of Ethnicity in the Rate of Beta Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis. (2020) (2)
- The Effect of Ethnicity in the Rate of Beta Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis. (2020) (2)
- Response to Cundy (2001) (2)
- Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657–664 (2019) (2)
- Abstract 12919: Relationship of Aortic Distensibility to Cardiovascular Disease Risk Factors in Type 1 Diabetes Mellitus: the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study (2011) (2)
- Greater reductions in C-reactive protein with rosiglitazone than with glyburide or metformin despite greater weight gain (2007) (1)
- Nonparametric test of stochastic ordering for multiple longitudinal measures. (1995) (1)
- Greenhouse, Samuel W (2005) (1)
- Analysis of Event‐Time Data (2008) (1)
- Emergency Hospitalizations for Adverse Drug Events (2012) (1)
- Erratum. Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2017;40:1010–1016 (2020) (1)
- Are Randomized Trials in Kidney Disease Worthwhile (1984) (1)
- Methods for a longitudinal quantitative outcome with a multivariate Gaussian distribution multi‐dimensionally censored by therapeutic intervention (2014) (1)
- Cardiometabolic Risk Factors and Incident Cardiovascular Disease Events in Women vs Men With Type 1 Diabetes (2022) (1)
- Covariate‐Adaptive Randomization (2015) (1)
- DNA methylation mediates development of HbA1c-associated complications in type 1 diabetes (2020) (1)
- Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes. (2022) (1)
- Intention-to-Treat Analysis (2008) (1)
- Sample size and power for survival time studies with nonuniform entry, losses to follow-up, noncompliance, and stratification (1985) (1)
- Data sharing is desirable, but benefits should not be exaggerated (2015) (1)
- Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC (2020) (1)
- Serum urate and cardiovascular events in the DCCT/EDIC study (2021) (1)
- Relative Risk Estimates and Tests for Two Independent Groups (2008) (1)
- Serum urate and cardiovascular events in the DCCT/EDIC study (2021) (1)
- Stratified‐Adjusted Analysis for Two Independent Groups (2008) (1)
- Identifying Change Points in a Covariate Effect on Time-to-Event Analysis with Reduced Isotonic Regression (2014) (1)
- Response to Comment on Lachin et al. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes Care 2022;45:2445-2448. (2022) (1)
- EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR MORTALITY BY PREVALENT OR INCIDENT HEART FAILURE IN THE EMPA-REG OUTCOME TRIAL (2016) (1)
- A composite design for transition from a preliminary to a full‐scale study (2007) (1)
- Refining Measurement of Hemoglobin A1c. (2017) (1)
- ADOPT: The effectiveness of metformin versus glyburide in type 2 diabetes (2007) (1)
- Closed testing of each group versus the others combined in a multiple group analysis (2019) (1)
- Appendix: Statistical Theory (2008) (0)
- Inference for Stratified, Blocked, and Covariate‐Adjusted Analyses (2005) (0)
- Sample Size Determination: Overview (2014) (0)
- Coronary Artery Disease Events and Carotid Intima‐Media Thickness in Type 1 Diabetes in the DCCT/EDIC Cohort (2021) (0)
- 187-LB: Risk Factors for Lower Hip-Bone Density in Older Adults with Type 1 Diabetes (2020) (0)
- Late‐breaking Trials (2006) (0)
- 1541-P: Association between Urine Free Advanced Glycation End Products (AGEs) at Three Time Points during the DCCT/EDIC and Subsequent Risk of Microvascular Complications in Type 1 Diabetes (2019) (0)
- Erratum. (2021) (0)
- Response to Moses (1996) (0)
- Permutation tests following restricted randomization procedures (1990) (0)
- The Effects of Unobserved Covariates (2005) (0)
- Oxidative and Advanced Glycation End-Products Biomarkers and Their Association with the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC (2019) (0)
- Cost-Efficient Multiply Matched Case-Control Study Designs. (2022) (0)
- Advanced Glycation End Products (AGEs)-Role in Development and Progression of Kidney Disease in Type 1 Diabetes in DCCT/EDIC (2018) (0)
- Relationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE Cohort (2018) (0)
- Sample size evaluation for a multiply matched case-control study using the score test from a conditional logistic (discrete Cox PH) regression model. (2018) (0)
- Response‐Adaptive Randomization in Practice (2005) (0)
- 16. Intention-to-Treat Analysis (2014) (0)
- OR14-4 Early Glomerular Hyperfiltration and Long Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience (2019) (0)
- Author's Reply (0)
- Some Useful Results in Large Sample Theory (2005) (0)
- 286-OR: Biomedical Predictors of Cognitive Decline in Older Participants with T1DM: Longitudinal Follow-Up of the DCCT/EDIC Cohort (2020) (0)
- Applications of Maximum Likelihood and Efficient Scores (2008) (0)
- Balancing on Known Covariates (2005) (0)
- Increased incidence of fractures in women who received rosiglitazone in ADOPT (A Diabetes Outcome Progression Trial) (2007) (0)
- Biostatistics and Biomedical Science (2008) (0)
- Reminiscences of Jerry Cornfield (2013) (0)
- Abstract 13133: The Association of Coronary Artery Calcification (CAC) With Subsequent Cardiovascular Disease (CVD) in DCCT/EDIC (2018) (0)
- Practice of Epidemiology Models to Assess the Association of a Semiquantitative Exposure With Outcomes (2020) (0)
- Residual Beta-Cell Function in Long Duration Type 1 Diabetes (T1D) (2018) (0)
- Relationship of myocardial scar with cardiovascular disease risk factors in the diabetes control and complications trial (DCCT)/epidemiology of diabetes interventions and complications (EDIC) study (2010) (0)
- University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (afternoon panel session) (2018) (0)
- Informed consent in clinical investigations. (1977) (0)
- Randomization as a Basis for Inference (2005) (0)
- Refining Measurement of Hemoglobin A 1c (2017) (0)
- 445-P: Modified LDL-Immune Complexes (IC) and the Risk of CVD in Type 1 Diabetes (2019) (0)
- Early termination of the Diabetes Control and Complications Trial (2006) (0)
- Uric Acid and Cardiovascular Disease in Type 1 Diabetes (2018) (0)
- Some useful distribution-free multivariate estimators and tests for the analysis of repeated measures in a clinical trial (1991) (0)
- Randomization for Balancing Treatment Assignments (2005) (0)
- Changes in bone metabolism biomarkers in the ADOPT study (2008) (0)
- Abstract 15852: Treated Systolic Blood Pressure and Cardiovascular Risk in Adults With Hypertension and Type 2 Diabetes: Results From the TECOS Trial (2016) (0)
- Case‐Control and Matched Studies (2008) (0)
- EFFECTS OF EMPAGLIFLOZIN ON OVERALL HEART FAILURE BURDEN IN EMPA-REG OUTCOME (2016) (0)
- Large Sample Inference for Complete and Restricted Randomization (2005) (0)
- 1540-P: Plasma Advanced Glycation End Products (AGEs) at Three Time Points during the DCCT/EDIC Are Associated with Subsequent Risk of Microvascular Complications in Type 1 Diabetes (2019) (0)
- The minimum intensity of a mixed exposure that increases the risk of an outcome (2020) (0)
- Erratum. Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care 2013;36:2254-2261. (2022) (0)
- Large Sample Inference for Response‐Adaptive Randomization (2005) (0)
- Left Ventricular Structure, Tissue Composition, and Aortic Distensibility in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications. (2022) (0)
- Randomization in Practice (2005) (0)
- Restricted Randomization in Practice (2015) (0)
- Risk of severe hypoglycemia in T1DM over 30 years of follow-up in the DCCT/EDIC study (2018) (0)
- Relationships Between the Cumulative Incidences of Long-term Complications in Type 1 Diabetes: the DCCT/EDIC Study. (2022) (0)
- EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK (2016) (0)
- 09 Poisson regression direct adjustment comparison of lifetables (1997) (0)
- INTERPRETING COVARIATE EFFECTS IN REGRESSION MODELS : SEARCHING FOR SYNERGISM AND ANTAGONISM (2003) (0)
- Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. (2022) (0)
- S38 Joint estimation of the mean and overdispersion parameters of an overdispersed poisson distribution using quasi-likelihood (1997) (0)
- Inference for Response‐Adaptive Randomization (2015) (0)
- The Department of Statistics at The George Washington University (2012) (0)
- The Association of Coronary Artery Calcification (CAC) With Subsequent Incidence of Cardiovascular Disease (CVD) in DCCT/EDIC (2019) (0)
- Pancreatic Safety of Sitagliptin in the TECOS Trial (2017) (0)
- Analysis of recurrent events based on random interval count data (1986) (0)
- Abstract 16435: Myocardial Structural Remodeling and Tissue Composition by Cardiac Magnetic Resonance (CMR) in Relation to Metabolic Syndrome in Type 1 Diabetes: The DCCT/EDIC Study (2012) (0)
- Cost‐efficient clinical studies with continuous time survival outcomes (2021) (0)
- Minutes of the 21st General Assembly of the European Association for the Study of Diabetes (2004) (0)
- CLINICAL VARIATIONS HOLD IMPORTANT CLUES TO THE UNDERSTANDING AND IMPLEMENTATION OF THE DCCT RESULTS. AUTHORS' REPLIES (1996) (0)
- Intention‐to‐Treat: Overview (2014) (0)
- Clinical and Metabolic Characterization of Adults With Type 2 Diabetes by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) Cohort (2022) (0)
- Determinants of monotherapy failure in ADOPT - (A diabetes outcome progression trial) (2007) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With John M. Lachin?
John M. Lachin is affiliated with the following schools:
